MedPath

Tarlatamab

Generic Name
Tarlatamab
Drug Type
Biotech
CAS Number
2307488-83-9
Unique Ingredient Identifier
74X82ST8Q1

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: May 14, 2025

Comprehensive Report on Tarlatamab (Imdelltra)

I. Introduction to Tarlatamab (Imdelltra)

A. Overview and Development

Tarlatamab, also known by its development code AMG-757 and marketed under the brand name Imdelltra, is an innovative antineoplastic agent engineered and developed by Amgen.[1] It represents a significant advancement in immunotherapy, specifically as a first-in-class agent targeting Delta-like ligand 3 (DLL3).[1] The development of Tarlatamab has been driven by the critical unmet medical need in treating aggressive hematological malignancies and solid tumors, particularly extensive-stage small cell lung cancer (ES-SCLC), a disease notorious for its rapid progression and limited effective treatment options following initial platinum-based chemotherapy.[5]

The designation of Tarlatamab as a "first-in-class" bispecific T-cell engager (BiTE) targeting DLL3 signifies a novel therapeutic strategy for SCLC.[1] This unique position underscores its potential to significantly alter the treatment landscape for this challenging cancer, provided its efficacy and safety are robustly confirmed in broader patient populations and potentially in earlier lines of therapy. SCLC has long been characterized by poor prognoses and a lack of durable responses to conventional treatments beyond the first line. The introduction of a therapy with a distinct mechanism of action, such as Tarlatamab, offers new hope for patients who have exhausted standard therapeutic avenues.

B. Chemical and Physical Properties

Tarlatamab is a biologic medication with the following identifiers and characteristics:

  • DrugBank ID: DB17256 [1]
  • CAS Number: 2307488-83-9 [1]
  • Type: Biotech; specifically, it is a human monoclonal antibody engineered as a Bi-specific T-cell Engager (BiTE).[1]
  • Molecular Formula: C4664​H7139​N1259​O1454​S34​ [1]
  • Molar Mass: Approximately 105202.82 g·mol$^{-1}$ [1]
  • Source: Human [1]

Continue reading the full research report

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath